Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Drug Makers Join Trend Of Outsourcing Trials, Other Work

This article was originally published in PharmAsia News

Executive Summary

Japanese drug makers are joining the trend of outsourcing clinical trials to other countries. Daiichi Sankyo is moving its first trials to India beginning next month even though foreign tests cannot be used for drug approvals in Japan. But Daiichi Sankyo says trials are cheaper in India where the population is adopting Western eating habits, making them more suitable for drugs to be marketed in Western countries. Astellas Pharma plans trials in South Korea and Eisai is exporting clinical research work to Singapore and development in other Asian nations, particularly China and India. Smaller Japanese pharmas also are looking to join the trend. (Click here for more - a subscription may be required

You may also be interested in...



Japanese Pharma Looking Beyond Japan For Clinical Trials

TOKYO - Japanese pharmaceutical manufacturers are diversifying their Phase III clinical trials away from Japan to establish development footholds into fast-developing East Asia and other regions where costs are low and trial patients can be secured with ease

Teva Calls In Sanofi To Turbocharge Its Place In Blockbuster TL1A Inflammation Race

Signing a deal worth up to $1.5bn, Teva is hoping Sanofi’s dominance in immunology via the mega-blockbuster Dupixent can help it compete with frontrunners Pfizer/Roivant and Merck & Co in a new anti-inflammatory space.

Novo Mulls What To Do With Wegovy Windfall

The fortunes of the foundation that controls Novo Nordisk and backs a wide range of scientific, humanitarian and social causes are set to be transformed by the spectacular commercial success of the weight loss blockbuster Wegovy.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel